Rocuronium-induced neuromuscular block and reversibility with sugammadex at the corrugator supercilii and adductor pollicis muscles

Trial Profile

Rocuronium-induced neuromuscular block and reversibility with sugammadex at the corrugator supercilii and adductor pollicis muscles

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Dec 2015

At a glance

  • Drugs Sugammadex (Primary)
  • Indications Neuromuscular blockade
  • Focus Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 26 Nov 2015 Treatment arms has changed from 2 to 3 according to University Hospital Medical Information Network - Japan record.
    • 20 Sep 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top